Side-by-side comparison of AI visibility scores, market position, and capabilities
Boston e-commerce (PDD Holdings NASDAQ: PDD subsidiary) at $70.8B GMV, 416.5M monthly users; halted China-to-US direct shipments (2025) after de minimis elimination, pivoting to US local sellers competing with Amazon for discount commerce.
Temu is a Boston, Massachusetts-headquartered global e-commerce marketplace — owned by PDD Holdings (NASDAQ: PDD), the parent company of China's Pinduoduo — that launched in the United States in September 2022 with an ultra-low-price, direct-from-Chinese-manufacturer model under the tagline "Shop Like a Billionaire," reaching $70.8 billion in gross merchandise volume (GMV) and expanding to 90+ markets worldwide within three years. By Q2 2025, Temu reached 416.5 million monthly active users globally, accumulated 1.0 billion cumulative app downloads, and users spent an average of 21 minutes per day on the platform — engagement metrics exceeding Amazon, eBay, and AliExpress for average session duration. Temu captured an estimated 17% of the US e-commerce market by April 2024, becoming the most-downloaded shopping app in the US within two months of launch and the second most-used cross-border e-retailer globally after Amazon. PDD Holdings' $4.3 billion estimated marketing spend in 2024 (Super Bowl advertising, Meta and Google ad dominance) fueled this growth by subsidizing customer acquisition below cost. However, in early 2025, Temu made a pivotal operational change: following President Trump's executive order eliminating the de minimis customs exemption (which had allowed packages under $800 to enter the US duty-free, the economic foundation of Temu's direct-from-China shipping model), Temu halted direct China-to-US shipments and pivoted to US-based local seller fulfillment — fundamentally changing its supply chain model.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.